Loading
Every failed cancer drug, experiment and trial gets recorded in one open ledger, so nobody repeats a failure that has already cost years and millions.
Most preclinical negatives are never published, most discontinued compounds vanish with their data, and terminated trials often report nothing. The proposal is a ledger with structured entries (target, compound, model, endpoint, result, reason for stopping) required as a condition of public funding, journal publication and regulatory submission, with a safe harbour for industry deposition of discontinued asset data, and incentives (citations, credit) for negative-result deposition. Discontinued compounds with clean safety could be listed for repurposing.
Shares Secrecy and intellectual property block collaboration, Preclinical results do not reproduce.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Preclinical results do not reproduce, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Preclinical results do not reproduce, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.